Table 1 Patient demographics and disease characteristics
From: Chlamydia trachomatis enhances HPV persistence through immune modulation
Clinical parameter | HPV | CT/HPV | C. trachomatis | Control |
|---|---|---|---|---|
No. of patients | 53 | 37 | 30 | 30 |
Median age (range) | 36.22 ± 6.17(20–65) | 35.86 ± 5.42(21–63) | 33.43 ± 4.12(18–60) | 34.57 ± 7.29(22–60) |
Pathological diagnosis | ||||
Negative | 39(73.5%) | 22(59.4%) | 24(80.0%) | |
ASC-US | 6(11.3%) | 3(8.1%) | 3(10.0%) | |
LSIL | 5(9.4%)* | 8(21.6%) | 2(6.7%)* | |
HSIL | 3(5.7%)* | 4(10.8%) | 1(3.3%)* | |
Total | 53 | 37 | 30 | |